Highlights
– A 2025 systematic review and meta-analysis (Katsuragawa et al., Lancet Diabetes Endocrinol) pooled data from 24 observational cohorts (6,621 patients) and found that patients with unsuppressed renin after medical therapy for primary aldosteronism had lower cardiovascular event rates (pooled HR 0.43, 95% CI 0.23–0.80).
– The cardiovascular benefit was more pronounced with longer follow-up (≥5 years; pooled HR 0.33, 95% CI 0.19–0.57), while associations with renal outcomes were null and data on mortality were sparse.
